
Early Molecular Diagnosis of Cancer Proven More Cost-Effective Than Subsequent Treatment of Advanced Disease
Applying expensive diagnostic methods in clinical practice will ultimately cost society 5 to 10 times less than the expenditures associated with late-stage cancer treatment, including subsequent disability pensions and sick leave payments—these are the findings from a study conducted by researchers at the HSE Faculty of Economic Sciences Marina Kolosnitsyna and Anastasia Vladimirskaya in collaboration with colleagues at EVOGEN, a medical genetic laboratory, and the Department of Health of the Yamalo-Nenets Autonomous Okrug. The study results have been published in Social Aspects of Population Health.